Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Barsky SH, Siegal GP, Jannotta F, et al: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49:140,1983-147,
Kinoh H, Sato H, Tsunezuka Y, et al: MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 109:953,1996-959,
Nath D, Slocombe PM, Stephens PE, et al: Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 112:579,1999-587,
Goldberg G, Wilhelm SM, Kronberger A, et al: Human fibroblast collagenase: Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 261:6600,1986-6605,
Monsky WL, Kelly T, Lin C-Y, et al: Binding and localization of (M)r 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res 53:3159,1993-3164,
Rha SY, Yang WI, Kim JH, et al: Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5:875,1998-879,
Kurizaki T, Toi M, Tominaga T: Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Reports 5:673,1998-677,
Heppner KJ, Matrisian LM, Jensen RA, et al: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273,1996-282,
Ahmed A, Hanby A, Dublin E, et al: Stromelysin-3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 152:721,1998-728,
Nielsen BS, Sehested M, Kjeldsen L, et al: Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 77:345,1997-355,
Kawami H, Yoshida K, Ohsaki A, et al: Stromelysin-3 mRNA expression and malignancy: Comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res 13:2319,1993-2324,
Freije JMP, Díez-Itza I, Balbín M, et al: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766,1994-16773,
Ueno H, Nakamura H, Inoue M, et al: Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57:2055,1997-2060,
Polette M, Nawrocki B, Gilles C, et al: MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 428:29,1996-35,
Pyke C, Ralfkiær E, Tryggvason K, et al: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359,1993-365,
Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al: Stromal expression of 72 kda Type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141:389,1992-396,
Soini Y, Pääkkö P, Autio-Harmainen H: Genes of laminin B1 chain, alpha-1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am J Pathol 142:1622,1993-1630,
Bolon I, Devouassoux M, Robert C, et al: Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 150:1619,1997-1629,
Canete-Soler R, Litzky L, Lubensky I, et al: Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol 144:518,1994-527,
Anderson IC, Sugarbaker DJ, Ganju RK, et al: Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblast. Cancer Res 55:4120,1995-4126,
Stearns ME, Stearns M: Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 8:63,1996-67,
Stearns ME, Wang M: Type IV collagenase (Mr 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res 53:878,1993-883,
Montironi R, Lucarini G, Castaldini C, et al: Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res 16:2057,1996-2622,
Fishman DA, Bafetti LM, Stack MS: Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16:150,1996-159,
McDonnell S, Matrisian LM: Stromelysin in tumor progression and invasion. Cancer Metastasis Rev 9:305,1991-319,
MacDougall JR, Bani MR, Lin Y, et al: The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cell. Cancer Res 55:4174,1995-4181,
Ichikawa Y, Ishikawa T, Momiyama N, et al: Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase-7, matrilysin. Clin Exp Metastasis 16:3,1998-8,
Yamamoto H, Adachi Y, Itoh F, et al: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59:3313,1999-3316,
Schultz RM, Silberman S, Persky B, et al: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48:5539,1988-5545,
Tsunezuka Y, Kinoh H, Takino T, et al: Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 56:5678,1996-5683,
Koop S, Khokha R, Schmidt EE, et al: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54:4791,1994-4797,
Powell WC, Knox JD, Navre M, et al: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53:417,1993-422,
Itoh T, Tanioka M, Yoshida H, et al: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048,1998-1051,
Witty JP, McDonnell S, Newell K, et al: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 54:4805,1994-4812,
Davies B, Brown PD, East N, et al: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087,1993-2091,
Wang X, Fu X, Brown PD, et al: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726,1994-4728,
Eccles SA, Box GM, Court WJ, et al: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56:2815,1996-2822,
Price A, Shi Q, Morris D, et al: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5:845,1999-854,
Johnston MR, Mullen JBM, Pagura M, et al: AG3340, a novel matrix metalloproteinase inhibitor, decreases growth and metastasis of orthotopic human lung cancer in a nude rat preclinical model system. Proc Am Assoc Cancer Res 39:302,1998 (abstr)
Nozaki S, Sissons S, Casazza AM, et al: Inhibition of human breast cancer regrowth and pulmonary metastasis by BAY 12-9566 in athymic mice. Proc Am Assoc Cancer Res 39:301,1998 (abstr)
Flynn C, Bull C, Eberwein D, et al: Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Assoc Cancer Res 39:301,1998 (abstr)
Van den Oord JJ, Paemen L, Opdenakker G, et al: Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151:665,1997-670,
Shalinsky DR, Zou H, McDermott CD, et al: AG3340, a selective MMP inhibitor, has broad antiangiogenic activity across oncology and ophthalmology models in vivo. Proc Am Assoc Cancer Res 40:66,1999 (abstr)
Anderson IC, Shipp MA, Docherty AJ, et al: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56:715,1996-718,
Neri A, Goggin B, Kolis S, et al: Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 39:302,1998 (abstr)
Giavazzi R, Garofalo A, Ferri C, et al: Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 4:985,1998-992,
Beattie GJ, Smyth JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 4:1899,1998-1902,
Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Cancer 23:526,1997-531,
Bodurtha A, Eisenhauer E, Steward W, et al: Phase I-II study of marimastat (BB-2516) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 16:493a,1997 (abstr 1775)
Parsons SL, Watson SA, Griffin NR, et al: An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 47:47,1996 (abstr) (suppl 5)
Evans J, Bramhall S, Carmichael J, et al: A phase II study of marimastat (BB-2516) in advanced pancreatic cancer. Ann Oncol 7:51,1996 (abstr) (suppl 5)
Rosemurgy A, Harris J, Langleben A, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 15:207,1996 (abstr 470)
Poole C, Adams M, Barley V, et al: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor in patients with advanced ovarian cancer. Ann Oncol 7:68,1996 (abstr) (suppl 5)
Boasberg P, Harbaugh B, Eisenberger M, et al: Marimastat in patients with hormone refractory prostate cancer: A dose-finding study. Proc Am Soc Clin Oncol 16:316a,1997 (abstr 1126)
Boasberg P, Harbaugh B, Roth B, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 15:258,1996 (abstr 671)
Erlichman C, Adjei A, Alberts S, et al: Phase I study of BAY 12-9566: A matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 17:217a,1998 (abstr 837)
Goel R, Hirte H, Shah A, et al: Phase I study of the metalloproteinase inhibitor Bayer 12-9566. Proc Am Soc Clin Oncol 17:217a,1998 (abstr 840)
Grochow L, O’Reilly S, Humphrey R, et al: Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor, BAY 12-9566. Proc Am Soc Clin Oncol 17:213a,1998 (abstr 822)
Hirte H, Goel R, Bennett K, et al: Phase I study of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced cancer. Ann Oncol 9:75,1998 (abstr) (suppl 2)
Levitt NC, Eskens F, Propper DJ, et al: A phase I pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 17:213a,1998 (abstr 823)
Macaulay VM, O’Byrne KJ, Saunders MP, et al: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5:513,1999-520,
Primrose J, Bleiberg H, Daniel F, et al: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. Ann Oncol 7:35,1996 (abstr) (suppl 5)
Zaknoen S, Wolff R, Cox J, et al: Marimastat in advanced progressive colorectal cancer: A dose-finding study. Proc Am Soc Clin Oncol 16:273a,1997 (abstr 968)
Malfetano J, Teng N, Barter J, et al: Marimastat in patients with advanced cancer of the ovary: A dose-finding study. Proc Am Soc Clin Oncol 16:373a,1997 (abstr 1331)
Nemunaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4:1101,1998-1109,
Rosemurgy A, Buckels J, Charnley R: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 18:261a,1999 (abstr 1005)
Adams M, Thomas H: A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 17:217a,1998 (abstr 838)
Carmichael J, Ledermann JA, Woll PJ, et al: Phase 1B study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 17:232a,1998 (abstr 888)
Gradishar W, Sparano J, Cobleigh M, et al: A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:144a,1998 (abstr 548)
Chouinard E, Goel R, Hirte HW, et al: A phase I interaction study between BAY 12-9566 and doxorubicin in cancer patients. Proc Am Assoc Cancer Res 40:84,1999 (abstr)
Ikeda T, Murakami K, Hayakawa Y, et al: Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor. Anticancer Res 18:4259,1998-4265,